ReviewDiscover oncology2025
A prognostic model based on gamma-glutamyl transpeptidase-derived neutrophil-platelet for predicting intrahepatic recurrence in hepatocellular carcinoma.
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
aimsThis study aims to investigate the prognostic significance of the combined GNR and GPR in patients with early-stage hepatitis B virus-associated hepatocellular carcinoma (HBV-HCC).
methodsRetrospective analysis was performed on clinical data of 145 HBV-infected patients with early-stage HCC (ESHCC) who underwent radiofrequency ablation (RFA) and/or surgical resection. Patients were randomly allocated to training (n = 103) and validation (n = 42) cohorts for further survival analysis and model verification. The area under the receiver operating characteristic curves (ROC) was used for evaluating the diagnostic performance of ERM-model. And at the optimal cutoff, a survival analysis on all patients was conducted. Simultaneously, all patients were divided into different subgroups to evaluating ERM-Model.
resultsMultivariate Cox analysis identified GNR and GPR as independent risk factors for postoperative intrahepatic recurrence (IHR). The combined biomarkers panel demonstrated superior diagnostic accuracy (AUC = 0.812) compared to AFP (AUC = 0.773). Survival analysis showed a significantly higher 2-year cumulative non-IHR rate in the low-risk group (logit(P) < 0.398) verus the high-risk group (logit(P) ≥ 0.398, p < 0.001). Subgroup analysis of all patients that ERM-model showed differencesin HCC stage stratification, with higher diagnostic accuracy for BCLC stage A cases compared to BCLC stage 0 cases.
conclusionsGNR and GPR are valuable predictors of IHR in ESHCC. Clinicians can leverage this dual-marker model to assess risk and tailor personalized follow-up strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.